These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 9496254

  • 1. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
    Umeda T, Eguchi Y, Okino K, Kodama M, Hattori T.
    J Pathol; 1997 Dec; 183(4):388-97. PubMed ID: 9496254
    [Abstract] [Full Text] [Related]

  • 2. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 3. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R, Landete JM, España F, Vázquez C, Fuster C, Almenar SM, Ramón LA, Radtke KP, Estellés A.
    Thromb Res; 2007 Jan; 120(5):753-62. PubMed ID: 17258797
    [Abstract] [Full Text] [Related]

  • 4. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
    Feng Q, Liu Y, Liu K, Byrne S, Liu G, Wang X, Li Z, Ockleford CD.
    Placenta; 2000 Jan; 21(2-3):184-93. PubMed ID: 10736241
    [Abstract] [Full Text] [Related]

  • 5. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
    Kim SJ, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, Shin E, Koyama H, Inaji H, Takai S.
    Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
    [Abstract] [Full Text] [Related]

  • 6. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
    Robert C, Bolon I, Gazzeri S, Veyrenc S, Brambilla C, Brambilla E.
    Clin Cancer Res; 1999 Aug; 5(8):2094-102. PubMed ID: 10473092
    [Abstract] [Full Text] [Related]

  • 7. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC, Holzscheiter L, Kotzsch M, Luther T, Kiechle-Bahat M, Sweep FC, Span PN, Schmitt M, Magdolen V.
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [Abstract] [Full Text] [Related]

  • 8. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
    Shiomi H, Eguchi Y, Tani T, Kodama M, Hattori T.
    Am J Pathol; 2000 Feb; 156(2):567-75. PubMed ID: 10666386
    [Abstract] [Full Text] [Related]

  • 9. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brünner N, Harbeck N, Klijn JG, Foekens JA.
    Cancer Res; 2004 Jul 01; 64(13):4563-8. PubMed ID: 15231667
    [Abstract] [Full Text] [Related]

  • 10. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
    de Vries TJ, Kitson JL, Silvers WK, Mintz B.
    Cancer Res; 1995 Oct 15; 55(20):4681-7. PubMed ID: 7553649
    [Abstract] [Full Text] [Related]

  • 11. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 12. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N.
    Clin Cancer Res; 1997 Feb 01; 3(2):233-9. PubMed ID: 9815678
    [Abstract] [Full Text] [Related]

  • 13. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug 01; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

  • 14. Factors involved in the plasminogen activation system in human breast tumours.
    Damjanovich L, Turzó C, Adány R.
    Thromb Haemost; 1994 Jun 01; 71(6):684-91. PubMed ID: 7974332
    [Abstract] [Full Text] [Related]

  • 15. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
    Christensen L, Wiborg Simonsen AC, Heegaard CW, Moestrup SK, Andersen JA, Andreasen PA.
    Int J Cancer; 1996 May 16; 66(4):441-52. PubMed ID: 8635858
    [Abstract] [Full Text] [Related]

  • 16. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer.
    Nielsen BS, Sehested M, Timshel S, Pyke C, Danø K.
    Lab Invest; 1996 Jan 16; 74(1):168-77. PubMed ID: 8569179
    [Abstract] [Full Text] [Related]

  • 17. Transcriptional regulation of tissue- and urokinase-type plasminogen activator genes by thrombin in human fetal lung fibroblasts.
    Hayakawa Y, Tazawa S, Ishikawa T, Niiya K, Sakuragawa N.
    Thromb Haemost; 1995 Aug 16; 74(2):704-10. PubMed ID: 8585010
    [Abstract] [Full Text] [Related]

  • 18. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.
    Cancer Res; 2002 Aug 15; 62(16):4617-22. PubMed ID: 12183417
    [Abstract] [Full Text] [Related]

  • 19. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
    Jahkola T, Toivonen T, von Smitten K, Virtanen I, Wasenius VM, Blomqvist C.
    Br J Cancer; 1999 Apr 15; 80(1-2):167-74. PubMed ID: 10389993
    [Abstract] [Full Text] [Related]

  • 20. Differential effects of fibroblast growth factors on expression of genes of the plasminogen activator and insulin-like growth factor systems by human breast fibroblasts.
    Sieuwerts AM, Martens JW, Dorssers LC, Klijn JG, Foekens JA.
    Thromb Haemost; 2002 Apr 15; 87(4):674-83. PubMed ID: 12008951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.